NEWAMSTERDAM PHARMA CO NV (NAMS) Stock Analyst Earnings Estimates
NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 97.5M | 13.254M -86.41% | 32.622M 146.13% | 9.185M -71.84% | 18.295M 99.18% | 125.02M 583.36% | 292.82M 134.22% | 596.43M 103.68% | 1.067B 78.90% | 1.409B 32.05% | 1.719B 22.00% | |||
| EBITDA YoY % growth | -126.66K | -1.352M -967.65% | -3.867M -185.96% | -238.852M -6,076.67% | -192.78M 19.29% | -156.06M 19.05% | -105.06M 32.68% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -127.66K | -1.366M -970.25% | -3.939M -188.30% | -195.241M -4,856.62% | -190.345M 2.51% | -201.958M -6.10% | -198.989M 1.47% | -144.506M 27.38% | -31.238M 78.38% | 197.22M 731.35% | 607.79M 208.18% | 946.02M 55.65% | 1.196B 26.42% | |
| Operating Margin | N/A | N/A | -4.04% | -1,473.07% | -583.49% | -2,198.78% | -1,087.67% | -115.59% | -10.67% | 33.07% | 56.96% | 67.14% | 69.58% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.21 -1,306.89% | -2.12 4.09% | -1.87 11.71% | -1.74 6.66% | -1.28 26.70% | -0.01 99.04% | 1.62 13,365.00% | 4.25 162.02% | 5.39 26.71% | 7.05 30.85% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 14.68% | -0.53 49.69% | -0.45 -9.46% | -0.45 -151.76% | -0.46 6.82% | -0.43 19.67% | -0.44 2.27% | -0.46 -2.03% | -0.49 -5.26% |
| Revenue Q2Q % growth | 1.791M 127.40% | 2.71M 93.43% | 535.796K -76.49% | 547.74K -98.12% | 560.704K -68.69% | 183.6K -93.23% | 367.2K -31.47% | 612K 11.73% | 856.8K 52.81% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -54.296M -3.48% | -49.103M 3.25% | -51.412M 9.88% | -51.151M 2.57% | -51.267M 5.58% | -41.49M 15.50% | -43.295M 15.79% | -46.703M 8.69% | -51.513M -0.48% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.18 67.54% | -0.51 | 0.33 | 64.67% |
| Q2 2024 Q2Q % growth | -0.41 11.09% | -0.59 | 0.18 | 30.32% |
| Q1 2024 Q2Q % growth | -1.06 -163.31% | -0.54 | -0.52 | -97.14% |
| Q4 2023 Q2Q % growth | -0.58 -26.72% | -0.61 | 0.03 | 4.67% |
| Q3 2023 Q2Q % growth | -0.55 4.59% | -0.50 | -0.06 | -11.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 29.111M 877.73% | 1.91M | 27.201M | 1,424.14% |
| Q2 2024 Q2Q % growth | 2.279M -76.17% | 1.406M | 873K | 62.09% |
| Q1 2024 Q2Q % growth | 1.401M -45.10% | 1.778M | -377K | -21.20% |
| Q4 2023 Q2Q % growth | 787.59K -99.19% | 1.998M | -1.21M | -60.58% |
| Q3 2023 Q2Q % growth | 2.977M | 2.291M | 686.42K | 29.96% |
| Q2 2023 Q2Q % growth | 9.562M | 2.794M | 6.768M | 242.23% |
| Q4 2022 Q2Q % growth | 97.5M | 3.561M | 93.939M | 2,637.99% |
| Q3 2022 Q2Q % growth | 1.687M | -1.687M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -16.39% |
| Revenue | 0% | 0% | 0% | 86.41% |